In yesterday’s Wall Street session, 89bio Inc (NASDAQ:ETNB) shares traded at $9.01, up 0.11% from the previous session.
ETNB stock price is now 14.84% away from the 50-day moving average and 8.33% away from the 200-day moving average. The market capitalization of the company currently stands at $1.06B.
On January 12, 2024, RBC Capital Mkts Downgraded its previous ‘Outperform’ rating to ‘Sector Perform’ on the stock reducing its target price from $24 to quote $15, while ‘Oppenheimer’ rates the stock as ‘Perform’
In other news, McWherter Charles, Director bought 10,000 shares of the company’s stock on Jan 22 ’25. The stock was bought for $67,100 at an average price of $6.71. Upon completion of the transaction, the Director now directly owns 25,000 shares in the company, valued at $0.23 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 21 ’25, Director McWherter Charles bought 5,000 shares of the business’s stock. A total of $32,750 was incurred on buying the stock at an average price of $6.55. This leaves the insider owning 15,000 shares of the company worth $0.14 million. A total of 4.21% of the company’s stock is owned by insiders.
During the past 12 months, 89bio Inc has had a low of $5.99 and a high of $16.63. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 11.65, and a quick ratio of 11.65. The fifty day moving average price for ETNB is $7.8463 and a two-hundred day moving average price translates $8.32495 for the stock.
The latest earnings results from 89bio Inc (NASDAQ: ETNB) was released for 2024-09-30. The company reported revenue of $151.94 million for the quarter, compared to $39.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 286.17 percent.
